Some alterations such as CDKN2A/B loss, PTEN, EGFR, NF1, and TERT promoter mutations have been shown to be associated with very poor clinical outcomes in patients with BRAF-altered gliomas (17). This evidence concerns the gene CDKN2A and glioma.